- Home
- MQY vs HELP Comparison
MQY vs HELP Comparison
Compare MQY & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MQY | HELP |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 787.3M | 889.9M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MQY | HELP |
|---|---|---|
| Price | $10.75 | $12.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 448.7K | ★ 1.5M |
| Earning Date | 01-01-0001 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.83 | $3.76 |
| 52 Week High | $11.94 | $14.35 |
Technical Indicators
Market Signals| Indicator | MQY | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 25.57 | 60.40 |
| Support Level | N/A | $11.26 |
| Resistance Level | $11.50 | $14.35 |
| Average True Range (ATR) | 0.06 | 0.82 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 2.86 | 41.36 |
Price Performance
Historical ComparisonAbout MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.